Suppr超能文献

耐多药结核病患者诊断前流失率低但治疗前流失率高:来自印度金奈的一项运筹学研究。

Low pre-diagnosis attrition but high pre-treatment attrition among patients with MDR-TB: An operational research from Chennai, India.

作者信息

Shewade Hemant Deepak, Nair Dina, Klinton Joel S, Parmar Malik, Lavanya J, Murali Lakshmi, Gupta Vivek, Tripathy Jaya Prasad, Swaminathan Soumya, Kumar Ajay M V

机构信息

International Union Against Tuberculosis and Lung Disease (The Union), South-East Asia Office, New Delhi, India.

National Institute for Research in Tuberculosis (NIRT), Chennai, India.

出版信息

J Epidemiol Glob Health. 2017 Dec;7(4):227-233. doi: 10.1016/j.jegh.2017.07.001. Epub 2017 Jul 6.

Abstract

BACKGROUND

Worldwide, there's concern over high pre-diagnosis and pre-treatment attritions or delays in Multidrug resistant tuberculosis (MDR-TB) diagnosis and treatment pathway (DTP). We conducted this operational research among patients with presumptive MDR-TB in north and central Chennai, India to determine attrition and turnaround times (TAT) at various steps of DTP and factors associated with attrition.

METHODS

Study was conducted in Revised National Tuberculosis Control Programme setting. It was a retrospective cohort study involving record review of all patients with presumptive MDR-TB (eligible for DST) in 2014.

RESULTS

Of 628 eligible for DST, 557 (88%) underwent DST and 74 (13%) patients were diagnosed as having MDR-TB. Pre-diagnosis and pre-treatment attrition was 11% (71/628) and 38% (28/74) respectively. TAT [median (IQR)] to test from eligibility for DST and initiate DR-TB treatment from diagnosis were 14 (9,27) and 18 (13,36) days respectively. Patients with smear negative TB and detected in first quarter of 2014 were less likely to undergo DST. Patients in first quarter of 2014 had significantly lower risk of pre-treatment attrition.

CONCLUSION

There was high uptake of DST. However, urgent attention is required to reduce pre-treatment attrition, improve TAT to test from eligibility for DST and improve DST among patients with smear-negative TB.

摘要

背景

在全球范围内,耐多药结核病(MDR-TB)诊断和治疗途径(DTP)中的高诊断前和治疗前流失率或延迟令人担忧。我们在印度金奈北部和中部的疑似耐多药结核病患者中开展了这项运筹学研究,以确定DTP各步骤的流失率和周转时间(TAT)以及与流失相关的因素。

方法

该研究在修订后的国家结核病控制规划环境中进行。这是一项回顾性队列研究,涉及对2014年所有疑似耐多药结核病(符合药敏试验条件)患者的记录审查。

结果

在628名符合药敏试验条件的患者中,557名(88%)接受了药敏试验,74名(13%)患者被诊断为耐多药结核病。诊断前和治疗前的流失率分别为11%(71/628)和38%(28/74)。从符合药敏试验条件到进行药敏试验以及从诊断到开始耐多药结核病治疗的TAT[中位数(四分位间距)]分别为14(9,27)天和18(13,36)天。涂片阴性结核病患者以及在2014年第一季度被检测出的患者接受药敏试验的可能性较小。2014年第一季度的患者治疗前流失风险显著较低。

结论

药敏试验的接受率较高。然而,需要迫切关注以减少治疗前流失率,缩短从符合药敏试验条件到进行试验的TAT,并提高涂片阴性结核病患者的药敏试验率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65cd/7384575/8c0fccb39387/JEGH-7-4-227-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验